Design, synthesis and anti-inflammatory activity of structurally simple anthranilic acid congeners devoid of ulcerogenic side effects

Chemical and Pharmaceutical Bulletin

Volumn 60, Issue 10, 2012, Pages 1290-1300

  Eissa, Amal Abdel Haleem Mohamed ^a   Soliman, Gamal Abd El Hakeem ^b   Khataibeh, Moayad Hussein ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Anthranilic acid derivative; Anti inflammatory activity; Hepatotoxicity evaluation; Nephrotoxicity evaluation; Ulcerative colitis

Indexed keywords

2 [4 CHLORO 2 [2 [2 (CYCLOHEXYLCARBAMOTHIOYL)HYDRAZINE CARBONYL]PHENYLAMINO] BENZOYL] N CYCLOHEXYLHYDRAZINE CARBOTHIOAMIDE; 2 [4 CHLORO 2 [2 [2 (ETHYLCARBAMOTHIOYL)HYDRAZINE CARBONYL]PHENYLAMINO]BENZOYL] N ETHYLHYDRAZINE CARBTHIOAMIDE; 2 [4 CHLORO 2 [2 [2 (PHENYLCARBAMOTHIOYL)HYDRAZINE CARBONYL]PHENYLAMINO]BENZOYL] N PHENYLHYDRAZINE CARBOTHIOAMIDE; 4 CHLORO 2 [2 (HYDRAZINECARBONYL)PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (1 4 TOLYLETHYLIDENE) 2 [2 [2 (1 4 TOLYLETHYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (1 PHENYLETHYLIDENE) 2 [2 [2 (1 PHENYLETHYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (1 PHENYLPROPYLIDENE) 2 [2 [2 (1 PHENYLPROPYLIDENE)HYDRAZINECARBONYL] PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (2,4,6 TRIMETHOXYBENZYLIDENE) 2 [2 [2 (2,4,6 TRIMETHOXYBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (3,4 DIMETHOXYBENZYLIDENE) 2 [2 [2 (3,4 DIMETHOXYBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (4 CHLOROBENZYLIDENE) 2 [2 [2 (4 CHLOROBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (4 HYDROXY 3,5 DIMETHYLBENZYLIDENE) 2 [2 [2 (4 HYDROXY 3,5 DIMETHYLBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (4 HYDROXYBENZYLIDENE) 2 [2 [2 (4 HYDROXYBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (4 METHOXYBENZYLIDENE) 2 [2 [2 (4 METHOXYBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' (FURAN 2 YLMETHYLENE) 2 [2 [2 (FURAN 2 YLMETHYLENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' [1 (4 HYDROXYPHENYL)ETHYLIDENE] 2 [2 [2 [1 (4 HYDROXYPHENYL)ETHYLIDENE]HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' [1 (4 HYDROXYPHENYL)PROPYLIDENE] 2 [2 [2 [1 (4 HYDROXYPHENYL)PROPYLIDENE]HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' [1 (4 METHOXYPHENYL)ETHYLIDENE] 2 [2 [2 [1 (4 METHOXYPHENYLETHYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; 4 CHLORO N' [4 (TRIFLUROMETHYL)BENZYLIDENE] 2 [2 [2 (4 TRIFLUROMETHYLBENZYLIDENE)HYDRAZINECARBONYL]PHENYLAMINO]BENZOHYDRAZIDE; ALANINE AMINOTRANSFERASE; ANTHRANILIC ACID DERIVATIVE; ASPARTATE AMINOTRANSFERASE; CARRAGEENAN; CREATININE; MEFENAMIC ACID; METHYL 4 CHLORO 2 [2 (METHOXYCARBONYL)PHENYLAMINO]BENZOATE; N' [1 (4 BROMOPHENYL)ETHYLIDENE] 2 [2 [2 [1 (4 BROMOPHENYL)ETHYLIDENE]HYDRAZINECARBONYL]PHENYLAMINO] 4 CHLOROBENZOHYDRAZIDE; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIPYRETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HOT PLATE TEST; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PAW EDEMA; RAT; SUBSTITUTION REACTION; TOXICITY TESTING; ULCERATIVE COLITIS; UREA BLOOD LEVEL; WRITHING TEST;

ALANINE TRANSAMINASE; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPYRETICS; ASPARTATE AMINOTRANSFERASES; COLITIS, ULCERATIVE; COLON; CREATINE; KIDNEY; KIDNEY FUNCTION TESTS; LETHAL DOSE 50; LIVER; LIVER FUNCTION TESTS; MALE; MICE; ORTHO-AMINOBENZOATES; RATS; RATS, SPRAGUE-DAWLEY; ULCER; UREA;

EID: 84867192926     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.c12-00516     Document Type: Article

References (55)

1. Sano H., Noguchi T., Tanatani A., Miyachi H., Hashimoto Y., Chem. Pharm. Bull., 52, 1021-1022 (2004).
2. Herschman H. R., Biochim. Biophys. Acta, 1299, 125-140 (1996).
3. Xu X. C., Anticancer Drugs, 13, 127-137 (2002).
4. Jiménez P., García A., Santander S., Piazuelo E., Curr. Pharm. Des., 13, 2261-2273 (2007).
5. Wuest F., Kniess T., Bergmann R., Pietzsch J., Bioorg. Med. Chem., 16, 7662-7670 (2008).
6. Ghodsi R., Zarghi A., Daraei B., Hedayati M., Bioorg. Med. Chem., 18, 1029-1033 (2010).
7. Lu X., Zhang H., Li X., Chen G., Li Q. S., Luo Y., Ruan B. F., Chen X. W., Zhu H. L., Bioorg. Med. Chem., 19, 6827-6832 (2011).
8. Gadad A. K., Palkar M. B., Anand K., Noolvi M. N., Boreddy T. S., Wagwade J., Bioorg. Med. Chem., 16, 276-283 (2008).
9. Borhade N., Pathan A. R., Halder S., Karwa M., Dhiman M., Pamidiboina V., Gund M., Deshattiwar J. J., Mali S. V., Deshmukh N. J., Senthilkumar S. P., Gaikwad P., Tipparam S. G., Mudgal J., Dutta M. C., Burhan A. U., Thakre G., Sharma A., Deshpande S., Desai D. C., Dubash N. P., Jain A. K., Sharma S., Nemmani K. V., Satyam A., Chem. Pharm. Bull., 60, 465-481 (2012).
10. Abouzid K., Frohberg P., Lehmann J., Decker M., Med. Chem., 3, 433-438 (2007).
11. Abouzid M. A. K., Youssef M. K., Ahmed E. A. A., Al-Zuhair H. H., Med. Chem. Res., 14, 26-39 (2005).
12. Suizu M., Muroya Y., Kakuta H., Kagechika H., Tanatani A., Nagasawa K., Hashimoto Y., Chem. Pharm. Bull., 51, 1098-1102 (2003).
13. Joo Y., Kim H.-S., Woo R.-S., Park C. H., Shin K.-Y., Lee J.-P., Chang K.-A., Kim S., Suh Y.-H., Mol. Pharmacol., 69, 76-84 (2006).
14. Reddy M. V. R., Billa V. K., Pallela V. R., Mallireddigari M. R., Boominathan R., Gabriel J. L., Bioorg. Med. Chem., 16, 3907-3916 (2008).
15. Dhaneshwar S. S., Gairola N., Kandpal M., Vadnerkar G., Bhatt L., Rathi B., Kadam S. S., Eur. J. Med. Chem., 44, 3922-3929 (2009).
16. Ragab F. A., Eid N. M., Hassan G. S., Nissan Y. M., Chem. Pharm. Bull., 60, 110-120 (2012).
17. Patrono C., Dunn M. J., Kidney Int., 32, 1-12 (1987).
18. Schneider V., Lévesque L. E., Zhang B., Hutchinson T., Brophy J. M., Am. J. Epidemiol., 164, 881-889 (2006).
19. Rossat J., Maillard M., Nussberger J., Brunner H. R., Burnier M., Clin. Pharmacol. Ther., 66, 76-84 (1999).
20. Swan S. K., Rudy D. W., Lasseter K. C., Ryan C. F., Buechel K. L., Lambrecht L. J., Pinto M. B., Dilzer S. C., Obrda O., Sundblad K. J., Gumbs C. P., Ebel D. L., Quan H., Larson P. J., Schwartz J. I., Musliner T. A., Gertz B. J., Brater D. C., Yao S. L., Ann. Intern. Med., 133, 1-9 (2000).
21. Schlondorff D., Kidney Int., 44, 643-653 (1993).
22. Woywodt A., Schwarz A., Mengel M., Haller H., Zeidler H., Köhler L., J. Rheumatol., 28, 2133-2135 (2001).
23. Rasheed A., Theja I., Ashok Kumar K. C., Lavanya Y., Ravindra Royal P., Vamsee Krishna S., Der Pharma Chemica, 1, 59-71 (2009).
24. Makhija T. D., Somani R. R., Der Pharmacia Lettre, 2, 300-309 (2010).
25. Rasheed A., Ashok Kumar K. C., Int. J. Curr. Pharm. Res., 1, 47-55 (2009).
26. Mishra A., Veerasamy R., Jain P. K., Dixit V. K., Agrawal R. K., Eur. J. Med. Chem., 43, 2464-2472 (2008).
27. Akhter M., Husain A., Azad B., Ajmal M., Eur. J. Med. Chem., 44, 2372-2378 (2009).
28. Bekhit A. A., El-Sayed O. A., Aboulmagd E., Park J. Y., Eur. J. Med. Chem., 39, 249-255 (2004).
29. Fadeyi O. O., Obafemi A. C., Adewunmi O. C., Iwalewa O. E., Afr. J. Biotechnol., 3, 426-431 (2004).
30. Abou El Ella A. D., Taha A. R., Bull. Fac. Pharm. Cairo Univ., 45, 267-281 (2007).
31. Eissa M. A. A., Bull. Fac. Pharm. Cairo Univ., 36, 99-105 (1998).
32. Abou-Seri S. M., Eur. J. Med. Chem., 45, 4113-4121 (2010).
33. Novoa de Armas H., Paneque Quevedo A., Henao Martinez J. A., Powder Diffraction, 13, 175-177 (1998).
34. Ebeid Y. M., Mikhael N. A., El-Moghazy M. S., Eissa A.-H. A., Bull. Fac. Pharm. Cairo Univ., 32, 361-368 (1994).
35. Buck W. B., Osweiter G. D., Van Gelder A., "Clinical and Diagnostic Veterinary Toxicology," 2nd ed., Kendall, Hunt Publishing Co., Iowa, 1976, p. 5211.
36. Winter C. A., Risley E. A., Nuss G. W., Proc. Soc. Exp. Biol. Med., 111, 544-547 (1962).
37. Abbott F. V., Melzack R., J. Brain Res., 251, 149-155 (1982).
38. Tjølsen A., Hole K., "Animal Models of Analgesia in the Pharmacology of Pain," Vol. 130, ed. by Dickenson A., Besson J., Springer, Berlin, 1997, pp. 1-20.
39. Loux J. J., DePalma P. D., Yankell S. L., Toxicol. Appl. Pharmacol., 22, 672-675 (1972).
40. Sharon P., Stenson W. F., Gastroenterology, 88, 55-63 (1985).
41. Nwanjo H. U., Okafor M. C., Oze G. O., J. Clin. Sci., 23, 10-12 (2005).
42. Panda N. C., "Kidney in: Textbook of Biochemistry and Human Biology," 2nd ed., Prentise Hall India, 1999, pp. 290-296.
43. Lorke D., Arch. Toxicol., 54, 251-287 (1983).
44. Paget G. E., Barnes J. M., Laurence D. R., Bacharach A. L., "Evaluation of Drug Activities: Pharmacometrics," Academic Press, London, 1964, pp. 135-166.
45. Eddy N. B., Leimbach D., J. Pharmacol. Exp. Ther., 107, 385-393 (1953).
46. Collier H. O., Dinneen L. C., Johnson C. A., Schneider C., Br. Pharmacol. Chemother., 32, 295-310 (1968).
47. Mascolo N., Izzo A. A., Autore G., Maiello F. M., Di Carlo G., Capasso F., J. Pharmacol. Exp. Ther., 272, 469-475 (1995).
48. Miller S., Hubble M., Duncan B., "Handbook of Solution-Focused Brief Therapy," Jossey-Bass, San Francisco, 1996.
49. Empey L. R., Jewell L. D., Garg M. L., Thomson A. B., Cladinin M. T., Fedorak R. N., Can. J. Physiol. Pharmacol., 69, 480-487 (1991).
50. Reitman S., Frankel S., Am. J. Clin. Pathol., 28, 55-60 (1957).
51. Walter M., Gerarade H., Microchem. J., 15, 231-243 (1970).
52. Henary R. J., Cannon D. C., Winkleman J. W., "Clinical Chemistry Principles and Techniques," 2nd ed., Harper & Roe, New York, 1974.
53. Doumas B. T., Watson W. A., Biggs H. G., Clin. Chim. Acta, 31, 87-96 (1971).
54. Wills M. R., Savory J., Ann. Clin. Lab. Sci., 11, 292-299 (1981).
55. Kroll M. H., Roach N. A., Poe B., Elin R. J., Clin. Chem., 33, 1129-1132 (1987).